MY ACCOUNT | NEWSLETTER |

Urinary sodium indices do not reliably differentiate stage B2 myxomatous mitral valve disease in dogs from healthy dogs.

Clinical evidence update from Frontiers in veterinary science


Clinical Context

Peer-reviewed veterinary literature continues to shape everyday decision-making for canine patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.

What the Study Evaluated

A study published in Frontiers in veterinary science in 2026 evaluated urinary sodium indices do not reliably differentiate stage B2 myxomatous mitral valve disease in dogs from healthy dogs..

Key Findings

Myxomatous mitral valve disease (MMVD) is associated with neurohormonal dysregulation, but practical markers for routine clinical use remain limited. This study evaluated whether spot urine sodium indices differ between healthy dogs and dogs with stage B2 MMVD and whether they are associated with echocardiographic indices of disease severity. In this prospective, single-center, cross-sectional study, 44 healthy dogs and 18 dogs with MMVD stage B2 were enrolled. Spot urine samples collected during routine visits were analyzed for urinary sodium concentration (uNa), urinary potassium concentration, urinary sodium-to-potassium ratio (uNa/uK),...

Why It Matters for Veterinary Professionals

For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for canine patients.

Practical Interpretation

The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.

Clinical Takeaway

Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.

Read the full article here.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Risk Factors, Biomarkers, and Risk Assessment Models for Prediction of Venous Thromboembolism in Ambulatory Patients with Advanced Lung Cancer.

Like0
Dislike0

Efficacy and Safety of Kanggan Mixture for Influenza: Protocol for a Multicenter Open-Label Randomized Controlled Trial.

Like0
Dislike0

Washington Animal Disease Diagnostic Lab

Like0
Dislike0

Canine and feline nutrition and dietetics - A guide for the general practitioner: A Practical Reference for Veterinary Professionals

Like0
Dislike0

Echocardiographic evaluation of aortic root size in cats with hypertrophic cardiomyopathy.

Like0
Dislike1

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top